MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

Search

Twist Bioscience Corp

Fechado

SetorSaúde

41.38 -0.02

Visão Geral

Variação de preço das ações

24h

Atual

Mín

39.05

Máximo

42.44

Indicadores-chave

By Trading Economics

Rendimento

-48M

-27M

Vendas

3M

99M

Margem de lucro

-27.41

Funcionários

979

EBITDA

3.2M

-21M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

-0.39% downside

Dividendos

By Dow Jones

Próximos Ganhos

2 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

669M

2.5B

Abertura anterior

41.4

Fecho anterior

41.38

Sentimento de Notícias

By Acuity

50%

50%

159 / 361 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Twist Bioscience Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

20 de jan. de 2026, 23:43 UTC

Conversa de Mercado

Gold Consolidates; May Face Technical Correction -- Market Talk

20 de jan. de 2026, 23:42 UTC

Conversa de Mercado

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

20 de jan. de 2026, 23:41 UTC

Ganhos

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

20 de jan. de 2026, 23:29 UTC

Conversa de Mercado

RBA Rate Hike in February Would Be a Painful One -- Market Talk

20 de jan. de 2026, 23:26 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de jan. de 2026, 23:26 UTC

Conversa de Mercado

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

20 de jan. de 2026, 22:45 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

20 de jan. de 2026, 22:45 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

20 de jan. de 2026, 22:44 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

20 de jan. de 2026, 22:44 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

20 de jan. de 2026, 22:43 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

20 de jan. de 2026, 22:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

20 de jan. de 2026, 22:27 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

20 de jan. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

20 de jan. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

20 de jan. de 2026, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

20 de jan. de 2026, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

20 de jan. de 2026, 22:18 UTC

Ganhos

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

20 de jan. de 2026, 22:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix's Live Events Are Boosting Retention, Co-CEO Says

20 de jan. de 2026, 22:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

20 de jan. de 2026, 22:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

20 de jan. de 2026, 22:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

20 de jan. de 2026, 22:13 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

20 de jan. de 2026, 22:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

20 de jan. de 2026, 22:10 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

20 de jan. de 2026, 22:08 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

20 de jan. de 2026, 22:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

20 de jan. de 2026, 22:06 UTC

Ganhos

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

20 de jan. de 2026, 22:00 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

ESG Roundup: Market Talk

20 de jan. de 2026, 21:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

Comparação entre Pares

Variação de preço

Twist Bioscience Corp Previsão

Preço-alvo

By TipRanks

-0.39% parte inferior

Previsão para 12 meses

Média 41.25 USD  -0.39%

Máximo 43 USD

Mínimo 39 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Twist Bioscience Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

5

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

31.56 / 38.6884Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

159 / 361 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat